Prospective, randomised multicenter phase II study (Funding: German Cancer Aid).

GLIAA is a prospective and randomized study investigating the value of high precision FET-PET-guided re-irradiation versus high precision MRI-T1c-guided re-irradiation in patients with recurrent glioblastoma.

Primary endpoint:
Progression-free survival.

Secondary endpoints:
Overall survival, quality of life, side effects after radiotherapy, localization of recurrences, volumetric evaluation of PET versus MRI.

Publications:

Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, Nestle U, Bock M, Yuh WTC, Meyer PT, Weber WA, Urbach H, Mader I, Grosu AL. Radiother Oncol.2018;[Epub ahead of print].

Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA10/ARO 2013-1). Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Götz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu AL. BMC Cancer 2016;16: 769

[(18)F] FET-PET imaging for treatment and response monitoring of radiation therapy in malignant glioma patients – A Review. Götz I, Grosu AL. Front Oncol 2013;3: 104 – 104.

An interindividual comparison of O-(2- [(18)F] fluoroethyl)-L-tyrosine (FET)- and L-[methyl-(11)C] methionine (MET)-PET in patients with brain gliomas and metastases. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA. Int J Radiat Oncol 2011;81: 1049 – 1058.

PET for radiation treatment planning of brain tumors. Grosu AL, Weber WA. Radiother Oncol 2010;96: 325 – 327.